AJANTPHARM.NS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 05:59):

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages...

Stats
Today's Volume	190 512
Average Volume	164 411
Market Cap	301.95B
EPS	INR0 ( 2024-05-01 )
Next earnings date	( INR23.80 ) 2024-07-24
Last Dividend	INR15.00 ( 2023-08-04 )
Next Dividend	INR0 ( N/A )
P/E	41.15
ATR14	INR3.73 (0.16%)

Volume Correlation

Long: 0.29 (neutral)

Short: 0.54 (weak)

Signal:(53.33) Neutral

Ajanta Pharma Limited Correlation

10 Most Positive Correlations
BHARATWIRE.NS	0.837
IZMO.NS	0.823
ASHIANA.NS	0.821
ASIANHOTNR.NS	0.805
AUROPHARMA.NS	0.801
GISOLUTION.NS	0.801

10 Most Negative Correlations
STARTECK.NS	-0.829
SEYAIND.NS	-0.806

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ajanta Pharma Limited Correlation - Currency/Commodity

0.16
( neutral )

0.32
( neutral )

0.03
( neutral )

0.26
( neutral )

-0.05
( neutral )

0.08
( neutral )

Ajanta Pharma Limited Financials

Annual	2023
Revenue:	INR42.09B
Gross Profit:	INR21.06B (50.05 %)
EPS:	INR64.82

FY	2023
Revenue:	INR42.09B
Gross Profit:	INR21.06B (50.05 %)
EPS:	INR64.82

FY	2022
Revenue:	INR37.43B
Gross Profit:	INR26.92B (71.93 %)
EPS:	INR45.89

FY	2022
Revenue:	INR32.84B
Gross Profit:	INR23.97B (73.00 %)
EPS:	INR54.97

Financial Reports:

No articles found.

Ajanta Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR7.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR15.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Ajanta Pharma Limited Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.36 - Stable (7.19%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.133	2002-12-17
Last Dividend	INR15.00	2023-08-04
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	20	--
Total Paid Out	INR73.42	--
Avg. Dividend % Per Year	0.57%	--
Score	3.25	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.36
Div. Directional Score	7.74	--

Next Divdend (Est)
(2024-08-29)

INR16.81 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

3.25

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR6.00	0.78%
2019	INR8.67	1.10%
2020	INR6.33	0.97%
2021	INR6.33	0.58%
2022	INR7.00	0.47%
2023	INR15.00	1.24%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SESHAPAPER.NS	Dividend Knight	2023-06-07	Annually	23	1.14%
MANAKCOAT.NS	Dividend Junior	2023-08-22	Sporadic	4	0.09%
GOODYEAR.NS	Dividend Knight	2023-07-26	Annually	5	4.02%
AVANTIFEED.NS	Dividend Junior	2023-08-03	Annually	14	0.86%
TRIL.NS	Dividend Junior	2023-07-27	Sporadic	17	0.22%
PILANIINVS.NS	Dividend Junior	2023-08-29	Annually	13	0.56%
JKCEMENT.NS	Dividend Junior	2023-08-01	Annually	19	0.37%
DEVIT.NS	Dividend Junior	2023-09-22	Annually	8	0.28%
SMSPHARMA.NS	Ex Dividend Junior	2023-09-22	Annually	18	0.12%
MINDTECK.NS	Dividend Junior	2023-08-04	Sporadic	8	0.28%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.194	1.500	6.12	9.18	[0 - 0.5]
returnOnAssetsTTM	0.176	1.200	4.13	4.96	[0 - 0.3]
returnOnEquityTTM	0.235	1.500	8.51	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.05	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.944	0.800	3.27	2.62	[0.8 - 2.5]
cashRatioTTM	0.146	1.500	-0.300	-0.450	[0.2 - 2]
debtRatioTTM	0.00761	-1.500	9.87	-10.00	[0 - 0.6]
interestCoverageTTM	147.56	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	16.08	2.00	4.64	9.28	[0 - 30]
freeCashFlowPerShareTTM	16.08	2.00	1.958	3.92	[0 - 20]
debtEquityRatioTTM	0.00989	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.683	1.000	1.951	1.951	[0.2 - 0.8]
operatingProfitMarginTTM	0.253	1.000	6.94	6.94	[0.1 - 0.6]
cashFlowToDebtRatioTTM	5.74	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.907	0.800	7.28	5.83	[0.5 - 2]
Total Score				10.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	37.25	1.000	6.34	0	[1 - 100]
returnOnEquityTTM	0.235	2.50	9.04	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	16.08	2.00	4.64	3.92	[0 - 30]
dividendYielPercentageTTM	1.698	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	16.08	2.00	4.64	9.28	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	3.80	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0481	1.000	-1.297	0	[0.1 - 0.5]
Total Score				5.36

Ajanta Pharma Limited

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, pediatric, respiratory and general health products, dermatology, ophthalmology, and pain management areas. It also provides multivitamins, antibiotics, eye drops, cough syrups, etc. The company serves in India, Africa, rest of Asia, the United States, and internationally. It supplies its products to government bodies, including armed forces, government hospitals, canteens, stores department, etc. The company was founded in 1973 and is headquartered in Mumbai, India.